No Data
No Data
Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Express News | Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
Top Premarket Gainers